Forty-five percent of providers interviewed by KLAS are planning to consolidate their CVIS products, but less than half plan to stick with their current vendor/solution. 

In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).